ArticleClinical and translational gastroenterology2021
Low-Grade Endotoxemia and Thrombosis in COVID-19.
Article in Clinical and translational gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Endotoxemia and its association with immune and coagulopathy responses in severe community-acquired pneumonia and COVID-19.Intensive care medicine experimental · 2026Article
- Bacteriome Signature in SARS-CoV-2-Infected Patients Correlates with Increased Gut Permeability and Systemic Inflammatory Cytokines.Microorganisms · 2025Article
- Lipopolysaccharide-Binding Protein (LBP) and Inflammatory Biomarkers in SARS-CoV-2 Hospitalized Patients.Journal of clinical medicine · 2025Article
- Blood Transcriptome Profiling Highlights the Role of Intestinal Bacterial Translocation in Severe COVID-19.Pathogens (Basel, Switzerland) · 2025Article
- Gut Microbiota in Heart Failure-The Role of Inflammation.Biomedicines · 2025Review
- Association Between NOX2-Mediated Oxidative Stress, Low-Grade Endotoxemia, Hypoalbuminemia, and Clotting Activation in COVID-19.Antioxidants (Basel, Switzerland) · 2024Article
- Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.Clinical and experimental medicine · 2024Article
- Dose-Dependent Effects of Lipopolysaccharide on the Endothelium-Sepsis versus Metabolic Endotoxemia-Induced Cellular Senescence.Antioxidants (Basel, Switzerland) · 2024Review
- Innate immune dysregulation in multisystem inflammatory syndrome in children (MIS-C).Scientific reports · 2023Article
- Risk factors for carbapenem-resistantJAC-antimicrobial resistance · 2023Article
- Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments.Pharmacological reports : PR · 2023Review
- Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond.Circulation research · 2023Review
- Hepatobiliary system and intestinal injury in new coronavirus infection (COVID-19): A retrospective study.World journal of clinical cases · 2023Article
- Intestinal barrier dysfunction as a key driver of severe COVID-19.World journal of virology · 2023Review
- Endotoxin tolerance and low activation of TLR-4/NF-κB axis in monocytes of COVID-19 patients.Journal of molecular medicine (Berlin, Germany) · 2023Article
- TIRAP, TRAM, and Toll-Like Receptors: The Untold Story.Mediators of inflammation · 2023Review
- Editorial: Gut permeability-related endotoxemia and cardiovascular disease: A new clinical challenge.Frontiers in cardiovascular medicine · 2023Article
- IL-6, IL-10, sFas, granulysin and indicators of intestinal permeability as early biomarkers for a fatal outcome in COVID-19.Immunobiology · 2022Article
- Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics.Expert review of clinical immunology · 2022Article
- Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment.Stem cell research & therapy · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with community-acquired pneumonia display enhanced levels of lipopolysaccharides (LPS) compared with controls, suggesting that low-grade endotoxemia may be implicated in vascular disturbances. It is unknown whether this occurs in patients with coronavirus 2019 (COVID-19) and its impact on thrombotic complications.
methodsWe measured serum levels of zonulin, a marker of gut permeability, LPS, and D-dimer in 81 patients with COVID-19 and 81 healthy subjects; the occurrence of thrombotic events in COVID-19 during the intrahospital stay was registered.
resultsSerum LPS and zonulin were higher in patients with COVID-19 than in control subjects and, in COVID-19, significantly correlated (R = 0.513; P < 0.001). Among the 81 patients with COVID-19, 11 (14%) experienced thrombotic events in the arterial (n = 5) and venous circulation (n = 6) during a median follow-up of 18 days (interquartile range 11-27 days). A logistic regression analysis showed that LPS (P = 0.024) and D-dimer (P = 0.041) independently predicted thrombotic events. DISCUSSION: The study reports that low-grade endotoxemia is detectable in patients with COVID-19 and is associated with thrombotic events. The coexistence of low-grade endotoxemia with enhanced levels of zonulin may suggest enhanced gut permeability as an underlying mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.